Tibolone for prevention and treatment of postmenopausal osteoporosis

Maturitas

Volumn 57, Issue 1, 2007, Pages 35-38

  Ettinger, Bruce ^a  

^a NONE   (United States)

Author keywords

Bone mineral density; Dosage; Fracture; Osteoporosis; Prevention; Tibolone; Treatment

Indexed keywords

ESTROGEN; GESTAGEN; OSTEOCALCIN; PLACEBO; TIBOLONE;

BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; FRACTURE; HUMAN; MENOPAUSE; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; STROKE; VASOMOTOR DISORDER;

AGED; ANDROGEN ANTAGONISTS; BONE DENSITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; NORPREGNENES; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 34247121322     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2007.02.008     Document Type: Review

References (12)

1. Lindsay R., and Hart A. Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br J Med 280 (1980) 1207-1209
2. Modelska K., and Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 87 (2002) 16-23
3. Berning B., van Kuijk J.W., Bennink H.J., Kicovic P.M., and Fauser B.C. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Bone 19 (1996) 395-399
4. Gallagher J., Baylink D.J., and McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 86 (2001) 4717-4726
5. Geusens P., Dequeker J., and Schot L.P. Non-linear increase in vertebral density induced by synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas 13 (1991) 155-162
6. Bjarnason N., Bjarnason J., Rosenquist C., and Christiansen C. Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 81 (1996) 2419-2422
7. Bjarnason N., Bjarnason J., and Christiansen C. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone 20 (1997) 151-155
8. Banks E, Beral V, Reeves G, Balkwill A, Barnes I, for the Million Women Study Collaborators. Fracture incidence in relation to the pattern of hormone therapy in postmenopausal women. JAMA 2004;291:2212-2220.
9. Cummings SR. LIFT study is discontinued. [Letter to the Editor] BMJ 2006;332:667.
10. Gambacciani M., Ciaponi M., Cappagli B., et al. A longitudinal evaluation of the effect of two doses of tibolone on bone density and metabolism in early postmenopausal women. Gynecol Endocrinol 18 (2004) 9-16
11. Swanson S.G., Drosman S., Helmond F.A., and Stathopoulos V.M. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multi-center, randomized, double-blind, placebo-controlled study. Menopause 13 (2006) 917-925
12. Roux C., Pelissier C., Fechtenbaum J., Loiseau-Peres S., and Benhamou C.L. Randomized, double-masked 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporos Int 13 (2002) 241-248